🇺🇸 SECLakefront Biotherapeutics NVQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:59:23·⟳ 抓取 05:00:27 +1m04s·⚡ 决策 09-02 05:12:32 +12m05s·55.6 天前
Lakefront Biotherapeutics 披露已宣布回购计划的例行进展：8月24-28日回购127,796股，均价€25.19，总额约€322万
本次6-K是2026年6月9日已公告回购计划的例行执行进展报告，仅披露5个交易日的回购明细（127,796股/€322万），无计划变更、无新增金额上限、无战略信息，属于纯行政性备案，不构成任何增量催化。
📄 原文Lakefront Biotherapeutics NV↗ 原文
----- f6k_090126.htm ----- 6-K 1 f6k_090126.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Lakefront Biotherapeutics（LKFT.US）
例行回购进展更新（计划6月9日已公告），无新增金额、条款变更或战略信息，不构成增量催化，无交易edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Lakefront Biotherapeutics 于2026年9月1日通过6-K提交回购进展新闻稿，报告8月24-28日在Euronext Amsterdam等市场回购127,796股、均价€25.19、总额约€322万。该回购计划早在6月9日已公告，本次仅为监管要求的定期执行进展披露，无计划条款变更、无新增授权金额、无业务或管线信息。对股价无增量定价信息，不构成可交易事件。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无需先例：例行回购进展不构成可交易催化，不进入先例研究
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 308 ms
{"result": "search_processed_events:agent query=`lakefront biotherapeutics share repurchase buyback | lakefront own shares acquisition | lkft 回购进展`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.6/72 小时、3904 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}
原文全文
展开原文 · 6,724 字
----- f6k_090126.htm -----
6-K
1
f6k_090126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On September 1, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated September 1, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: September 1, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via
a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
24/08/2026
XAMS
21,820
24.56
535,857.74
24.36
24.64
24/08/2026
TQEX
450
24.55
11,045.43
24.54
24.60
24/08/2026
CEUX
328
24.58
8,062.37
24.54
24.64
24/08/2026
AQEU
1,333
24.61
32,811.40
24.58
24.66
25/08/2026
XAMS
21,058
25.29
532,464.16
24.94
25.52
25/08/2026
TQEX
698
25.25
17,623.66
25.00
25.36
25/08/2026
CEUX
600
25.28
15,165.48
25.24
25.34
25/08/2026
AQEU
313
25.29
7,914.33
25.26
25.34
26/08/2026
XAMS
22,968
25.45
584,632.07
25.08
25.64
26/08/2026
TQEX
599
25.45
15,241.91
25.30
25.64
26/08/2026
CEUX
1,703
25.47
43,377.62
25.24
25.66
26/08/2026
AQEU
539
25.50
13,744.72
25.32
25.60
27/08/2026
XAMS
21,382
25.27
540,406.53
25.06
25.36
27/08/2026
TQEX
904
25.27
22,843.72
25.20
25.32
27/08/2026
CEUX
2,342
25.24
59,114.89
25.12
25.36
27/08/2026
AQEU
440
25.23
11,100.50
25.12
25.34
28/08/2026
XAMS
25,694
25.29
649,927.16
25.00
25.50
28/08/2026
TQEX
1,110
25.40
28,194.11
25.36
25.46
28/08/2026
CEUX
3,363
25.38
85,342.18
25.08
25.46
28/08/2026
AQEU
152
25.26
3,840.17
25.14
25.46
Total
127,796
25.19
3,218,710.15
24.36
25.66
As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated
to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established
a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri
Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
6-K
1
f6k_090126.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On September 1, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit 99.1. Press release dated September 1, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: September 1, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via
a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
24/08/2026
XAMS
21,820
24.56
535,857.74
24.36
24.64
24/08/2026
TQEX
450
24.55
11,045.43
24.54
24.60
24/08/2026
CEUX
328
24.58
8,062.37
24.54
24.64
24/08/2026
AQEU
1,333
24.61
32,811.40
24.58
24.66
25/08/2026
XAMS
21,058
25.29
532,464.16
24.94
25.52
25/08/2026
TQEX
698
25.25
17,623.66
25.00
25.36
25/08/2026
CEUX
600
25.28
15,165.48
25.24
25.34
25/08/2026
AQEU
313
25.29
7,914.33
25.26
25.34
26/08/2026
XAMS
22,968
25.45
584,632.07
25.08
25.64
26/08/2026
TQEX
599
25.45
15,241.91
25.30
25.64
26/08/2026
CEUX
1,703
25.47
43,377.62
25.24
25.66
26/08/2026
AQEU
539
25.50
13,744.72
25.32
25.60
27/08/2026
XAMS
21,382
25.27
540,406.53
25.06
25.36
27/08/2026
TQEX
904
25.27
22,843.72
25.20
25.32
27/08/2026
CEUX
2,342
25.24
59,114.89
25.12
25.36
27/08/2026
AQEU
440
25.23
11,100.50
25.12
25.34
28/08/2026
XAMS
25,694
25.29
649,927.16
25.00
25.50
28/08/2026
TQEX
1,110
25.40
28,194.11
25.36
25.46
28/08/2026
CEUX
3,363
25.38
85,342.18
25.08
25.46
28/08/2026
AQEU
152
25.26
3,840.17
25.14
25.46
Total
127,796
25.19
3,218,710.15
24.36
25.66
As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated
to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established
a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class
BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong
capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient
impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri
Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements
are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。